Evidence map›Paper›PMID 40712147›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Bioprinted Organoids: An Innovative Engine in Biomedicine.

Zhengwei Li, Kai Li, Cheng Zhang, Yingying Zhao, Yiyuan Guo, Jia He, Shiyuan Chang, Xinyi Fang, Kaizheng Liu, Pingping Zhu and 2 more

Abstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Organoids for disease modeling and treatment: state-of-the-art.Experimental hematology & oncology · 2026
    Review
  6. Biomaterials in organoid research: current state and future directions.Frontiers in bioengineering and biotechnology · 2026
    Review
  7. Review
  8. Review
  9. Bioprinted Organoids: An Innovative Engine in Biomedicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhengwei LiState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, School of Life Sciences, Zhengzhou University, Henan, 450001, China.ORCID https://orcid.org/0009-0008-0823-4350
Kai LiState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, School of Life Sciences, Zhengzhou University, Henan, 450001, China.
Cheng ZhangState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, School of Life Sciences, Zhengzhou University, Henan, 450001, China.
Yingying ZhaoState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, School of Life Sciences, Zhengzhou University, Henan, 450001, China.
Yiyuan GuoState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, School of Life Sciences, Zhengzhou University, Henan, 450001, China.
Jia HeState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, School of Life Sciences, Zhengzhou University, Henan, 450001, China.
Shiyuan ChangState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, School of Life Sciences, Zhengzhou University, Henan, 450001, China.
Xinyi FangResearch Center for Human Tissue and Organ Degeneration, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Kaizheng LiuResearch Center for Human Tissue and Organ Degeneration, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Pingping ZhuState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, School of Life Sciences, Zhengzhou University, Henan, 450001, China.
Zhenzhen ChenState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, School of Life Sciences, Zhengzhou University, Henan, 450001, China.
Changshun RuanResearch Center for Human Tissue and Organ Degeneration, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.ORCID https://orcid.org/0000-0001-6320-7189

Funding

China Postdoctoral Science Foundation GZC20241561Henan Province Outstanding Youth Science Foundation 242300421016Henan Province Science and Technology Research and Development Program 242102310339Henan Provincial Science and Technology R&D Plan Joint Foundation 232301420010National Key R&D Program of China 2023YFE0210500Natural Science Foundation of China Original Exploration Program 32450741Natural Science Foundation of Guangdong Province in China 2024B1515040018Shenzhen International Science and Technology Cooperation Project GJHZ20240218112602004Shenzhen Science and Technology Program JSGGKQTD20210831174330015
6 · The paper itself

Abstract

Bioprinted organoids integrate bioprinting technology with organoid research, enabling the simultaneous reconstruction of human tissue morphology and physiological function in vitro. This approach offers distinct advantages in organoid fabrication, particularly in terms of structural precision, tissue mimicry, and functional fidelity. By leveraging the complementary strengths of both technologies, bioprinted organoids allow for the fabrication of personalized, architecturally engineered models that more accurately replicate organogenesis, physiological processes, and disease progression. Herein, this review outlines the key advantages of bioprinted organoids, with a focus on their ability to precisely control morphology, dimensions, and spatial organization. Bioprinted organoids are further categorized into three types based on their cellular origins and summarize recent progress in their application for human tissue modeling. Finally, ongoing challenges and future possibilities are sketched out, offering insights for potential innovation and research directions in the field. Bioprinted organoids not only propel the advancement of organoid research but also drive the evolution of bioprinting technologies. This integrated approach represents a powerful synergy between biomanufacturing and clinical medicine to pave the way for a new era in biomedical science and personalized healthcare.

Indexed as

BioprintingOrganoidsTissue EngineeringHumansPrinting, Three-Dimensionaladult stem cellsbioprintingcancer cellsorganoidspluripotent stem cells

Identifiers

PMID40712147
PMCPMC12412588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.